Abstract
This study aimed to identify salivary metabolomic biomarkers for predicting the prognosis of oral squamous cell carcinoma (OSCC) based on comprehensive metabolomic analyses. Quantified metabolomics data of unstimulated saliva samples collected from patients with OSCC (n = 72) were randomly divided into the training (n = 35) and validation groups (n = 37). The training data were used to develop a Cox proportional hazards regression model for identifying significant metabolites as prognostic factors for overall survival (OS) and disease-free survival. Moreover, the validation group was used to develop another Cox proportional hazards regression model using the previously identified metabolites. There were no significant between-group differences in the participants’ characteristics, including age, sex, and the median follow-up periods (55 months [range: 3–100] vs. 43 months [range: 0–97]). The concentrations of 5-hydroxylysine (p = 0.009) and 3-methylhistidine (p = 0.012) were identified as significant prognostic factors for OS in the training group. Among them, the concentration of 3-methylhistidine was a significant prognostic factor for OS in the validation group (p = 0.048). Our findings revealed that salivary 3-methylhistidine is a prognostic factor for OS in patients with OSCC.
Highlights
Oral cancer occurs in the oral cavity, with oral squamous cell carcinoma (OSCC) accounting for 90% of all cases of oral cancer
We aimed to identify salivary metabolomic biomarkers for predicting the prognosis of OSCC
This study analyzed the relationships between salivary metabolites and the prognosis of OSCC
Summary
Oral cancer occurs in the oral cavity, with oral squamous cell carcinoma (OSCC) accounting for 90% of all cases of oral cancer (https://gco.iarc.fr/). The oral cavity can be visualized without using special devices; OSCC is assumed to be detected. Most OSCCs are frequently detected in advanced stages [1, 2], with these OSCCs showing a poor prognosis. There has been no substantial improvement in the long-term survival rate of OSCC in advanced stages over the past few decades [3,4,5,6]. There is a critical need to improve the prognosis of OSCC. It is critical to accurately predict the prognosis of OSCC before oncological treatment. Various clinicopathological parameters can accurately predict the prognosis of OSCC, with cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
